about
Adult bone marrow stromal cells differentiate into neural cells in vitroHigh-content flow cytometry and temporal data analysis for defining a cellular signature of graft-versus-host disease.Data management in the cell therapy production facility: the batch process record (BPR).Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host diseaseSerial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy.Mobilization of peripheral blood stem cells for autologous transplantation. Methods, mechanisms, and role in accelerating hematopoietic recovery.A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis.Sirolimus for treatment of steroid-refractory acute graft-versus-host disease.Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation.Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients.5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective.Part 4: Interaction between unproven cellular therapies and global medicinal product approval regulatory frameworks.Large-scale Ficoll gradient separations using a commercially available, effectively closed, system.Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell CarcinomaCombination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancerCell therapy medical tourism: time for actionFludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemiaApheresis and transplant of hematopoietic progenitor cells (HPC) from allogeneic donors of age above 60 yearsRetrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes
P50
Q28142055-B4590E98-C8A1-4ACA-A276-FFD1318BCAA6Q31113879-9E831014-0CF3-481B-983E-F6BBA274606DQ31152897-86F6292E-EE63-4456-BFD5-115EB98773CAQ34300883-DBB61BB6-2014-4C26-8603-88F4A75CF21FQ34560857-44463A34-BA52-496B-BA3C-E1EF4FF55B10Q35136043-C6A6D0F9-2AD6-4127-8C44-2074C8D62425Q37202298-56C4E32C-777D-493F-BA2A-04D457486852Q39627913-9A86C80D-D5A3-4BB6-A3CC-FCAB84360B0CQ40967626-1A1ABB05-E1DE-4FD1-B2C8-EF8045B6D2CBQ43183770-3EC3FB36-10A8-4A1C-A00F-CF056C84B1EDQ43228479-B591129D-F999-4193-97C3-C7DA7591D832Q44489096-2FF0AC0D-A362-41ED-B815-3D0FA8B6AEA3Q44944589-F28BB7C8-9619-46F5-B9C1-9EC711D12F6EQ45960014-EBFC1875-719D-468B-8DEA-6C6FE1053B1BQ46343524-9FFA0FBF-4734-4BEB-8EDD-D0817BF0B019Q46525846-C9DBC426-A5E2-41E0-91B8-34284E4728A1Q50584323-74FA3CCD-1B6A-4955-B890-8E662B78D54EQ51676874-7EB5D5E9-ABC9-4017-8E60-8DD8A5EBC6CFQ63170567-2D4961B5-7069-4F6E-B3F8-DD40FC303086Q64378051-2FF5B2AF-5B89-4797-864E-DFFB5C6BA1E6Q82439275-DBCFE571-C327-44A7-94FE-361C26649868Q83563979-AEBF2CE2-B59B-4022-973A-BFD17FC25C54Q84074588-CFE4B97A-2172-467F-B780-B119CF3AA31EQ84313483-70C0BBDB-35D2-4DC9-818A-577CE966C4B7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
William Janssen
@ast
William Janssen
@en
William Janssen
@es
William Janssen
@nl
William Janssen
@sl
Уильям Янсен
@ru
type
label
William Janssen
@ast
William Janssen
@en
William Janssen
@es
William Janssen
@nl
William Janssen
@sl
Уильям Янсен
@ru
prefLabel
William Janssen
@ast
William Janssen
@en
William Janssen
@es
William Janssen
@nl
William Janssen
@sl
Уильям Янсен
@ru
P106
P1153
7102276637
P21
P31
P496
0000-0001-5066-9608